MEMPHIS, Tenn. — For an equipment manufacturer that helped put perimeter-weighted irons on the map, the release of Blueprint, in 2019, marked another significant moment in Ping’s storied history.

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer-focused therapies. The biopharma has three ...

Blueprint Medicines is pulling back from one of its three areas of focus, dropping two non-small cell lung cancer (NSCLC) programs in response to early clinical data on the EGFR tyrosine kinase ...

Alexis Borisy, the founder of multiple biotech companies and self-dubbed “man of many hats,” may have to reduce two of his many duties. The Blueprint Medicines co-founder lost a majority vote for his ...

At the World Wide Technology Championship, Austin Eckroat’s win was part of a huge week for Ping across worldwide tours. The OEM had drivers win on the PGA, DP World, LPGA and Champions Tours. But on ...

When Jeff Albers joined Blueprint Medicines in 2014, the private company was a clinical-stage biotech. Now, the helmsman is handing down the reins after steering the firm through an IPO and two drug ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Sanofi said Monday it plans to buy Blueprint Medicines in a deal ...

We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. The pressure to get a ...